Metabolic syndrome and cardiometabolic risk: An update

Guido Grassi, Gino Seravalle, Fosca Quarti-Trevano, Raffaella Dell'ro, Michele Bombelli, Giuseppe Mancia

Research output: Contribution to journalArticle


Several lines of evidence show that metabolic syndrome represents an important therapeutic challenge for the forthcoming years. This is because of the epidemic burden of this multifaceted disease, the adverse impact on cardiovascular risk, as well as the problems posed in its management. This paper will provide an up-to-date report on metabolic syndrome and cardiometabolic risk, focusing in particular on the epidemiological profile of the disease, the impact on risk profile and target organ damage as well as some of the main pathophysiological features of the condition. The general therapeutic recommendations, provided by the 2007 European Society of Hypertension/European Society of Cardiology Guidelines, will be briefly discussed.

Original languageEnglish
Pages (from-to)7-16
Number of pages10
JournalBlood Pressure
Issue number1-2
Publication statusPublished - 2009



  • Antihypertensive treatment
  • Blood pressure
  • Cardiovascular risk
  • Metabolic syndrome
  • Obesity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this